Advertisement


Richard S. Finn, MD, on Advanced Hepatocellular Carcinoma: Expert Perspective

2016 Gastrointestinal Cancers Symposium

Advertisement

Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).



Related Videos

Gastroesophageal Cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).

Gastroesophageal Cancer

Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer (Abstract 6).

Solid Tumors

Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).

Pancreatic Cancer

James L. Abbruzzese, MD, on Pancreatic Cancer: Expert Perspective

James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.

Gastroesophageal Cancer

Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane

Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (Abstract 5).

Advertisement

Advertisement




Advertisement